videoDetails)

Biological E. Limited's COVID vaccine approved for trial, trial will be done on children of 5-18 years
)
The Drugs Controller General of India (DGCI) on Wednesday authorized Hyderabad-based Biological E. Ltd to conduct Phase 2 and 3 clinical trials for its anti-COVID vaccine named Corbevax on children aged 5 to 18 years with certain conditions.